| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -51.3 | -30.6 |
| EPS (diluted, $ a share) | $-0.15 | $-0.11 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ERAS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Erasca, Inc.: key numbers
- Share price
- $15.11Close, Nov 16
- Market cap
- $5.3B
- Shares outstanding
- 350.96MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Erasca, Inc.
All →Erasca Financial Results
Erasca reported third quarter 2026 financial results, highlighting a strong cash position of $948 million following an upsized $632.5 million public offering in July. The company received FDA Fast Track Designation for ERAS-0015 in metastatic pancreatic adenocarcinoma and is preparing to initiate three potentially registration-enabling trials in pancreatic and lung cancers starting in 2027.
- Term
- Q3 2026
“The emerging clinical profile of ERAS-0015 continues to support its potential as a foundational therapy across RAS-mutant cancers, both as a monotherapy and backbone for combination regimens.”
Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder
“With a strengthened balance sheet and experienced R&D leadership, we believe that we are positioned to execute our near-term milestones and advance programs addressing high unmet needs for patients with RAS-mutant cancers.”
Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder
Erasca Leadership Change
Erasca, Inc. announced that Nicholas (Nik) Chetwyn, Ph.D., will step down as Chief Operating Officer effective November 2, 2026. The departure is part of a leadership realignment to streamline the company's reporting structure as it focuses on its RAS-targeting programs.